Clinical Trial Update: Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of STA-5326 mesylate in moderate to severe Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• STA-5326 Mesylate (STA-5326 mesylate)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED